Seattle Times (Free subscription) | 07/11/2008
Dendreon reported a net quarterly loss of $17.3 million, down from $19.8 million for the same period last year.
The Puget Sound Business Journal (Free subscription) | 07/11/2008
Dendreon Corp. reported a third-quarter loss of $26.8 million, or a loss of 29 cents per share, which compares with a loss of $19.2 million, or a loss of 23 cents per share a year earlier. (DNDN)
The Earth Times Online Newspaper (Free subscription) | 07/11/2008
SEATTLE, Nov. 7 -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended September 30, 2008. Revenue for the third quarter of 2008 was $26,000 compared to $112,000 ...
The Earth Times Online Newspaper (Free subscription) | 07/11/2008
SEATTLE, Nov. 7 -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended September 30, 2008. Revenue for the third quarter of 2008 was $26,000 compared to $112,000 ...
Forbes (Free subscription) | 07/11/2008
Investors' disappointment in Dendreon has been built into the stock--the company announced in early October that it does not expect to file a new drug application with the U.S. Food and Drug Administration until at least mid-2009. Therefore, shareholders weren't surprised by the widening loss reported by the drug developer in the third quarter. Dendreon (nasdaq: ) were off slightly Friday...
Medical News Today (Free subscription) | 07/11/2008
Dendreon Corporation (Nasdaq: DNDN) will present a summary of Phase 1 clinical data of NEUVENGE(TM) (lapuleucel-T), an investigational active cellular immunotherapy, at the Chemotherapy Foundation Symposium in New York City.
PR News Wire (Free subscription) | 07/11/2008
SEATTLE, Nov. 7 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended September 30, 2008. Revenue for the third quarter of 2008 was $26,000 compared to $112,000 for the quarter ended September 30, 2007. Revenue for the nine months ended September 30, 2008 was $83,000 compared to $715,000 for the nine months ended September 30, 2007. Dendreon's...
PR News Wire (Free subscription) | 06/11/2008
SEATTLE, Nov. 6 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today will present a summary of Phase 1 clinical data of NEUVENGE(TM) (lapuleucel-T), an investigational active cellular immunotherapy, at the Chemotherapy Foundation Symposium in New York City. The presentation, which integrates the data from two clinical trials, highlights the safety profile, immune response and...
Pharmalot (Free subscription) | yesterday
A federal court judge has denied a bid to force the FDA to immediately make available documents involved in the controversy over the Provenge prostate-cancer vaccine. A group of cancer patients and investors in Dendreon, which is developing the vaccine, has been fighting in court to get the agency to approve Provenge, after a surprise [...]
PR News Wire (Free subscription) | 23/10/2008
-- Data Presented at 20th EORTC-NCI-AACR Symposium -- SEATTLE and GENEVA, Oct. 23 /PRNewswire-FirstCall/ -- Researchers from Dendreon Corporation (Nasdaq: ) today presented preclinical data on its lead small molecule candidate, D-3263, which targets Trp-p8 (a transmembrane cation channel protein also known as Trp-M8), supporting Trp-p8 as a therapeutic cancer target. The poster, titled,...
PR News Wire (Free subscription) | yesterday
... more cellular therapies that will launch over the next decade in the United States and/or Europe, Dendreon's Provenge will be the first market entrant following its approval for prostate cancer in 2009 in the United States. Another cellular therapy that will launch in the near-term, Osiris/Genzyme's Prochymal, will garner sales of $235 million in 2017 for the treatment of Crohn's disease,...
Business Wire (Free subscription) | 01/12/2008
... Inc., and prior to that, he was Senior Vice President, Medical and Regulatory Affairs at Dendreon Corporation where he oversaw the advancement of the company’s lead product for prostate cancer, Provenge® (sipuleucel-T), from phase 1 into phase 3 clinical testing.
Fool.com (Free subscription) | 31/10/2008
... in Motion (Nasdaq: )$46.99$122.06-61.5%Google (Nasdaq: )$368.75$679.23-45.7%Dendreon (Nasdaq: )$4.45$7.59-41.4%Amazon.com (Nasdaq: )$56.04$90.10-37.8%* XM Satellite Radio merged with Sirius to form Sirius XM Radio on July 29, 2008. The price on 10/29/2007 was taken from Capital IQ. The price on 10/28/2008 was derived by multiplying Sirius XM Radio’s adjusted closing price by 4.6, which is...
Seattle Post-Intelligencer (Free subscription) | 08/11/2008
... a release that this was the company's first profitable quarter.In other local earnings:Seattle's Dendreon Corp., a developer of prostate-cancer treatments, reported a widened third-quarter net loss of $26.8 million, or 29 cents per share, compared with a net loss of $19.2 million, or 23 cents per share, in third-quarter 2007. Quarterly revenue was also down: $26,000, compared with $112,000...
Pharmalot (Free subscription) | 27/10/2008
... in the way the FDA decided to delay approval for the vaccine, which is being developed by Dendreon. Here’s the petition filed with the US Supreme Court.
